CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ®, its ...

Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...

CRISPR-Cas9 removed an extra chromosome 21 from some Down syndrome cells in the lab. Learn what the 30.6% result means and ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

CrWRKY4 transcriptional circuit in the Madagascar periwinkle that acts as both accelerator and brake on the biosynthesis of ...

Most of any gains (or lack thereof) from here will be driven by just three factors.

CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical ...

A single intravenous infusion of an experimental CRISPR-Cas9 therapy cut LDL cholesterol by 52.5% in patients who received ...

A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were still present one year ...

CRISPR halves model-generation time and cuts costs by ~40%, while automation, aquatic models, genetic testing and cryobanking boost efficiency and client retention.Dublin, Oct. 07, 2026 (GLOBE ...

In a small first-in-human trial, a single CRISPR-Cas9 infusion that switches off the ANGPTL3 gene in the liver kept LDL ...

ZUG, Switzerland, BOSTON - CRISPR Therapeutics (Nasdaq: CRSP), announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited ...